OLMA
OLMA clinical trials: Olema Oncology, Inc.
Every trial on ClinicalTrials.gov where Olema Oncology, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 6
- Trials linked
- 6
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
OLMA on the catalyst calendar · OLMA registry changes
- Primary completion May 30, 2027Sponsor estimatePhase 1NCT06784193Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsOlema Oncology, Inc. · Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)RecruitingOLMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 3NCT07085767Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerOlema Oncology, Inc. · Breast CancerRecruitingOLMALeadNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 1NCT05508906Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerOlema Oncology, Inc. · Metastatic Breast CancerActive, not recruitingOLMALeadPFECollaboratorNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2026Sponsor estimatePhase 3NCT06016738OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerOlema Oncology, Inc. · Breast CancerActive, not recruitingOLMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2024ActualPhase 1/Phase 2NCT04505826A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast CancerOlema Oncology, Inc. · Hormone Receptor Positive Breast CarcinomaCompletedOLMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2026Sponsor estimatePhase 1NCT05266105A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer PatientsOlema Oncology, Inc. · Breast CancerActive, not recruitingOLMALeadPFECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 6 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner